PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7188759

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
OMEROS CORPORATION	12/23/2021

RECEIVING PARTY DATA

Name:	RAYNER SURGICAL INC.
Street Address:	THE RIDLEY INNOVATION CENTRE,10 DOMINION WAY, WEST SUSSEX
City:	WORTHING
State/Country:	EUROPEAN UNION
Postal Code:	BN148AQ

PROPERTY NUMBERS Total: 11

Property Type	Number
Application Number:	12799981
Application Number:	13420456
Application Number:	14075588
Application Number:	14186146
Application Number:	14946435
Application Number:	17366659
Application Number:	17405269
Application Number:	15278514
Application Number:	14061039
Application Number:	14721151
Application Number:	16276337

CORRESPONDENCE DATA

Fax Number: (206)224-0779

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: GEORGE E. RENZONI, PH.D.

Address Line 1: CHRISTENSEN O'CONNOR JOHNSON KINDNESS

Address Line 2: 1201 THIRD AVENUE, SUITE 3600 Address Line 4: SEATTLE, WASHINGTON 98101

PATENT REEL: 059353 FRAME: 0191

507141915

ATTORNEY DOCKET NUMBER:	4210-G001
NAME OF SUBMITTER:	RAINEE LOCKE
SIGNATURE:	/Rainee Locke/
DATE SIGNED:	02/22/2022

Total Attachments: 24

source=4210-G001 Patent Assignment Agreement#page1.tif source=4210-G001 Patent Assignment Agreement#page2.tif source=4210-G001 Patent Assignment Agreement#page3.tif source=4210-G001_Patent_Assignment_Agreement#page4.tif source=4210-G001_Patent_Assignment_Agreement#page5.tif source=4210-G001 Patent Assignment Agreement#page6.tif source=4210-G001 Patent Assignment Agreement#page7.tif source=4210-G001_Patent_Assignment_Agreement#page8.tif source=4210-G001 Patent Assignment Agreement#page9.tif source=4210-G001 Patent Assignment Agreement#page10.tif source=4210-G001 Patent Assignment Agreement#page11.tif source=4210-G001_Patent_Assignment_Agreement#page12.tif source=4210-G001 Patent Assignment Agreement#page13.tif source=4210-G001 Patent Assignment Agreement#page14.tif source=4210-G001 Patent Assignment Agreement#page15.tif source=4210-G001_Patent_Assignment_Agreement#page16.tif source=4210-G001_Patent_Assignment_Agreement#page17.tif source=4210-G001 Patent Assignment Agreement#page18.tif source=4210-G001 Patent Assignment Agreement#page19.tif source=4210-G001 Patent Assignment Agreement#page20.tif source=4210-G001_Patent_Assignment_Agreement#page21.tif source=4210-G001_Patent_Assignment_Agreement#page22.tif source=4210-G001 Patent Assignment Agreement#page23.tif source=4210-G001 Patent Assignment Agreement#page24.tif

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "**Assignment**") dated and effective as of December 23, 2021 at 12:01 a.m. Eastern Time (the "**Effective Date**"), is entered into by and between:

- (1) Omeros Corporation, a Washington corporation having its business address at 210 Elliott Avenue West, Seattle, Washington 98119 ("**Assignor**"); and
- (2) Rayner Surgical Inc., a Delaware corporation, having its business address at The Ridley Innovation Centre, 10 Dominion Way, Worthing, West Sussex, BN148AQ, United Kingdom ("Assignee").

Assignor and Assignee are collectively referred to as the "Parties" and individually referred to as a "Party." Capitalized terms not defined herein have the definitions set forth in that certain Asset Purchase Agreement entered into by and among Assignor, Assignee and, solely for the purposes of Article V and Section 6.24 of the Asset Purchase Agreement, Rayner Surgical Group Limited, dated as of December 1, 2021 (the "Asset Purchase Agreement").

WHEREAS, Assignor desires to sell, assign, transfer, convey and deliver to Assignee, and Assignee desires to acquire, all rights, title, and interest that Assignor may hold in and to the Patents set forth on <u>Schedule A</u> attached hereto and to the inventions and discoveries covered by each of the foregoing (collectively, the "**Assigned Patents**").

NOW, THEREFORE, in consideration of the foregoing, the mutual agreements and covenants set forth in the Asset Purchase Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

- 1. Assignment of Assigned Patents. Effective as of the Effective Date and subject to the receipt by Assignor of the Upfront Payment in accordance with the Asset Purchase Agreement, Assignor hereby sells, assigns, transfers, conveys and delivers to Assignee, and Assignee hereby accepts, all of Assignor's entire rights, title and interests in and to the Assigned Patents, including Assignor's entire rights, title and interests in and to any reissues and extensions thereof to be obtained in any country, and any and all continuing applications thereof, including divisional, continuation and continuation-in-part applications, substitute applications, and applications claiming benefit of an earlier filed provisional application, the right to claim priority based on any of the assigned patent rights, and all rights to bring an Action, whether at law or in equity, after the Effective Date, for past, present or future infringement of any of the Assigned Patents against any Person, and all rights to obtain or recover any damages, profits, injunctive relief and other relief with respect thereto.
- 2. <u>No Representations and Warranties</u>; <u>Asset Purchase Agreement Controls</u>. Any warranty or liability of Assignor in relation to the Assigned Patents shall be exclusively governed by the provisions of the Asset Purchase Agreement. The Assigned Patents shall be assigned and transferred under their current legal status "as is" unless explicitly stated otherwise in the Asset Purchase Agreement. In the event that any provision or term of this Assignment may be construed to conflict or be inconsistent with any provision or term of the Asset Purchase Agreement, the provision or term in the Asset Purchase Agreement shall control.

- 3. Recordation and Maintenance. After the Effective Date, Assignee shall be responsible for the registration/recordal of the transfer of the Assigned Patents in the official registers, for compliance with any deadlines for doing so and for the preparation of all documents necessary for such registrations/recordals. All related costs and expenses shall be borne exclusively by Assignee. Assignor hereby authorizes Assignee to record this Assignment with the U.S. Patent and Trademark Office and with its foreign counterparts (EPO, EUIPO, INPI, WIPO, etc.). After the Effective Date, the Assignee shall be, and is, solely responsible for the prosecution and maintenance of the Assigned Patents.
- 4. <u>Further Action</u>. Subject to and in accordance with Section 6.8 of the Asset Purchase Agreement, at Assignee's request, Assignor shall use its commercially reasonable efforts to execute and deliver to Assignee such confirmatory assignments and further documents and instruments and shall take such action, in each case as may be required, or as Assignee may reasonably request, to effect the assignment of the Assigned Patents to Assignee, and the registration/recordal of the transfer of the Assigned Patents.
- 5. <u>Entire Agreement</u>. This Assignment, including the Schedules attached hereto and the Asset Purchase Agreement, constitute the entire understanding and agreement between the Parties and supersede any prior understandings, agreements or representations by or among the Parties, written or oral, that may have related in any way to the subject matter hereof.
- 6. <u>Severability</u>. Any term or provision of this Assignment that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. Any provision of this Assignment held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.
- 7. <u>Governing Law.</u> This Assignment shall be governed by and construed in accordance with the Laws of the State of New York, excluding any conflicts or choice of Law rule or principle that might otherwise refer construction or interpretation of this Assignment to the substantive Law of another jurisdiction.
- 8. Waiver of Jury Trial. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS ASSIGNMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. EACH PARTY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HAVE BEEN INDUCED TO ENTER INTO THIS ASSIGNMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.
- 9. <u>Venue</u>. Notwithstanding anything to the contrary in this Assignment, each of the Seller and Purchaser, on behalf of themselves, their respective Subsidiaries and each of their

respective controlled Affiliates hereby: (a) agrees that any Action, whether in law or in equity, whether in contract or in tort or otherwise arising out of or relating to, this Assignment shall be subject to the exclusive jurisdiction of any federal or state court in the Borough of Manhattan, New York, New York and any appellate court thereof and irrevocably submits itself and its property with respect to any such Action to the exclusive jurisdiction of such court, (b) agrees not to bring or support or permit any of its controlled Affiliates to bring or support any Action of any kind or description, whether in law or in equity, whether in contract or in tort or otherwise arising out of or relating to this Assignment in any forum other than the United States District Court for the Southern District of New York or the Supreme Court of the State of New York sitting in the Borough of Manhattan, and any appellate court from any thereof, and (c) irrevocably waives, to the fullest extent that it may effectively do so, the defense of an inconvenient forum to the maintenance of such Action in any such court.

- by an instrument in writing signed on behalf of each of the Parties. Any waiver of any of the terms or conditions of this Assignment must be in writing and must be duly executed by or on behalf of the Party to be charged with such waiver. Except as expressly set forth in this Assignment, the failure of a Party to exercise any of its rights hereunder or to insist upon strict adherence to any term or condition hereof on any one occasion shall not be construed as a waiver or deprive that Party of the right thereafter to insist upon strict adherence to the terms and conditions of this Assignment at a later date. Further, no waiver of any of the terms and conditions of this Assignment shall be deemed to or shall constitute a waiver of any other term of condition hereof (whether or not similar).
- 11. <u>Counterparts</u>. This Assignment may be executed in counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. This Assignment and any amendments hereto, to the extent signed and delivered by means of digital imaging and electronic mail or a facsimile machine, shall be treated in all manner and respects as an original contract and shall be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person.

[Signature page follows]

IN WITNESS WHEREOF, the Parties hereto have duly executed and delivered this Assignment as of the Effective Date.

OMEROS CORPORATION

By:_

Name: Gregory A. Demopulos, M.D.

Title: Chairman and Chief Executive Officer

[SIGNATURE PAGE TO THE PATENT ASSIGNMENT AGREEMENT]

IN WITNESS WHEREOF, the Parties hereto have duly executed and delivered this Assignment as of the Effective Date.

OMEROS CORPORATION

By:		
Name:		
Title:		

RAYNER SURGICAL INC.

Darren Millington

By: Darren Millington (Dec 22, 28.23, 15.56 GMT)

Name: Darren Michael Millington

Title: Director

Schedule A – Assigned Patents

	Application So.	Printe Park	Publication	Publication Date	Partiers Number	Issue Date	Application State	Title
Austria	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Australia	2003261304	07/30/2003			2009248461	10/31/2013	Lapsed	Ophthalmologic Irrigation Solution and Method
Australia	2009248461	07/30/2003			2009248461	10/31/2013	Issued	Ophthalmologic Irrigation Solution and Method
Australia	2013202330	07/30/2003					Abandoned	Ophthalmologic Irrigation Solution and Method
Belgium	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Bulgaria	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Canada	2,493,581	07/30/2003	2493581	02/05/2004	2,493,581	12/23/2014	Issued	Ophthalmologic Irrigation Solution and Method
Canada	2,866,848	07/30/2003	2,866,848	02/05/2004	2,866,848	01/03/2017	Issued	Ophthalmologic Irrigation Solution and Method
Switzerland	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
China (People's Republic)	03823345.2	07/30/2003	1684701	10/19/2005	ZL03823345.2	10/17/2012	Issued	Ophthalmologic Irrigation Solution and Method
China (People's Republic)	200810137617.2	07/30/2003	101327325	12/24/2008			Abandoned	Ophthalmologic Irrigation Solution and Method
China (People's Republic)	201210320633.1	07/30/2003	103143022	06/12/2013			Abandoned	Ophthalmologic Irrigation Solution and Method
Cyprus, Republic of	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Czech Republic	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Germany	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Denmark	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Estonia	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
European Patent Convention	03 772122.2	07/30/2003	1534313	06/01/2005	1534313	10/17/2012	Granted	Ophthalmologic Irrigation Solution and Method
European Patent Convention	12180716.8	07/30/2003					Abandoned	Ophthalmologic Irrigation Solution and Method
European	12180714.3	07/30/2003					Abandoned	Ophthalmologic

[Schedule A to Patent Assignment]

Country	Application	Filing	Priblication					
Patent Convention				***				Irrigation Solution and Method
Spain	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Finland	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
France	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
United Kingdom	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Greece	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Hong Kong	06101875.2	02/14/2006	1081455A	05/19/2006	HK1081455	04/12/2013	Issued	Ophthalmologic Irrigation Solution and Method
Hong Kong	09105470.9	02/14/2006	1126662A	09/11/2009			Abandoned	Ophthalmologic Irrigation Solution and Method
Hong Kong	13113665.2	02/14/2006	1186124A	03/07/2014			Abandoned	Ophthalmologic Irrigation Solution and Method
Hungary	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Ireland	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Italy	03772122.2	07/30/2003	1534313		47653 2013	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Japan	2004-524225	07/30/2003	2006-504661	02/09/2006			Abandoned	Ophthalmologic Irrigation Solution and Method
Japan	2010-43527	07/30/2003	2010-132696	06/17/2010			Abandoned	Ophthalmologic Irrigation Solution and Method
Japan	2010-211424	07/30/2003	2011-6475	01/13/2011			Abandoned	Ophthalmologic Irrigation Solution and Method
Japan	2013-160106	07/30/2003	2013-216705	10/24/2013			Abandoned	Ophthalmologic Irrigation Solution and Method
Luxembourg	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Monaco	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Netherlands	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Patent Cooperation Treaty	PCT/US03/23871	07/30/2003	WO 2004/010894 A2	02/05/2004			Lapsed	Ophthalmologic Irrigation Solution and Method
Portugal	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic

Courses	Application	Filing	Peldication		Paten	Issue Date	0.00116.01.001	i i i
Name					Attabler			Irrigation Solution and Method
Romania	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Sweden	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Slovenia	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Slovakia	03772122.2	07/30/2003	1534313		1534313	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
Turkey	03772122.2	07/30/2003	1534313		TR2013 0257 T4	10/17/2012	Validated	Ophthalmologic Irrigation Solution and Method
United States of America	60/399,899	07/30/2002					Lapsed	Ophthalmologic Irrigation Solutions and Method
United States of America	10/630,626	07/30/2003	US-2004- 0072809-A1	04/15/2004			Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	12/799,981	05/05/2010	US-2010- 0311705-A1	12/09/2010	8,173,707	05/08/2012	Issued	Ophthalmologic Irrigation Solution and Method
United States of America	13/420,440	03/14/2012	US-2013- 0079344-A1	03/28/2013			Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	13/420,456	03/14/2012	US-2013- 0065869-A1	03/14/2013	8,586,633	11/19/2013	Issued	Ophthalmologic Irrigation Solution and Method
United States of America	14/075,588	11/08/2013	US-2014- 0221326-A1	08/07/2014	9,399,040	07/26/2016	Issued	Ophthalmologic Irrigation Solution and Method
United States of America	14/186,146	02/21/2014	20140235597	08/21/2014	9,278,101	03/08/2016	Issued	Ophthalmologic Irrigation Solution and Method
United States of America	15/414,930	01/25/2017	US 2017/0312295 A1	11/02/2017			Abandoned	Ophthalmologic Irrigation Solution and Method
Japan	2017-202579	07/30/2003					Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	14/946,435	11/19/2015	20160106761	04/21/2016	9,585,895	03/07/2017	Issued	Ophthalmologic Irrigation Solution and Method
United States of America	15/198,208	06/30/2016	US 2017/0100412 A1	04/13/2017			Abandoned	Ophthalmologic Irrigation Solution and Method
Austria	SZ 76/2015	12/17/2015			E b579 550	07/28/2017	Granted	Ophthalmologic Irrigation Solution and Method
Belgium	2015C/078	12/18/2015					Pending	Ophthalmologic Irrigation Solution and Method
Bulgaria	2015/0053	12/22/2015			BG/EP 1543313	09/20/2017	Granted	Ophthalmologic Irrigation Solution and Method
Cyprus,	SPCPHCY201505	12/16/2015			SPCPHCY201	02/25/2016	Granted	Ophthalmologic

CHENT NEW	Application So	Filing		Parking	Parent Number			Trip.
Republic of	5				5055			Irrigation Solution and Method
Czech Republic	SPC/CZ2015/443	12/17/2015			DO 443	05/21/2018	Granted	Ophthalmologic Irrigation Solution and Method
Germany	12 2015 000 111.4	12/17/2015			DE 12 2015 000 111.4	07/31/2023	Granted	Ophthalmologic Irrigation Solution and Method
Denmark	CA 2015 00072	12/17/2015			CR 2015 00072	01/03/2019		Ophthalmologic Irrigation Solution and Method
Estonia	C20150054	12/16/2015			00179	06/15/2016	Granted	Ophthalmologic Irrigation Solution and Method
Spain	C201530076	12/16/2015			C201530076	12/02/2016	Granted	Ophthalmologic Irrigation Solution and Method
Finland	C20150064	12/16/2015			C20150064	06/18/2021	Granted	Ophthalmologic Irrigation Solution and Method
France	15C0090	12/16/2015			15C0090	04/18/2016	Granted	Ophthalmologic Irrigation Solution and Method
United Kingdom	SPC/GB15/082	12/16/2015					Pending	Ophthalmologic Irrigation Solution and Method
Greece	20150800061	12/17/2015			8000621	12/05/2016	Granted	Ophthalmologic Irrigation Solution and Method
Hungary	S1500069	12/17/2015			S000302	12/04/2017	Granted	Ophthalmologic Irrigation Solution and Method
Ireland	2015/071	12/16/2015			2015/071	10/26/2018	Granted	Ophthalmologic Irrigation Solution and Method
Italy	1320 15000084739	12/17/2015			1320 15000084739	05/09/2016	Granted	Ophthalmologic Irrigation Solution and Method
Luxembourg	92 923	12/23/2015			1 534 313	11/08/2016	Granted	Ophthalmologic Irrigation Solution and Method
Netherlands	300784	12/18/2015					Pending	Ophthalmologic Irrigation Solution and Method
Portugal	733	12/18/2015			PT 1534313 W	01/29/2018	Granted	Ophthalmologic Irrigation Solution and Method
Romania	C2015 055	12/17/2015			C2015 055	06/16/2017	Granted	Ophthalmologic Irrigation Solution and Method
Sweden	1590074-9	12/17/2015			1590074-9	05/03/2018	Granted	Ophthalmologic Irrigation Solution and Method
Slovenia	C 2015 4 0059	12/18/2015			201540059	03/23/2016	Issued	Ophthalmologic Irrigation Solution and Method
Slovakia	SPC/PDO 5031- 2015	12/18/2015			DO 264	06/14/2017	Granted	Ophthalmologic Irrigation Solution and Method
Japan	2015-193350	07/30/2003	2016-14055	01/28/2016			Abandoned	Ophthalmologic

Country	Application No.	Filing	Paration					Tige
			N 1		Atteilber			Irrigation Solution and
Japan	2015-193351	07/30/2003	2016-14056	01/28/2016			Abandoned	Method Ophthalmologic Irrigation Solution and Method
Australia	2016201834	03/23/2016					Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	15/725,121	10/04/2017					Abandoned	Ophthalmologic Irrigation Solution and Method
Australia	2018200887	07/30/2003			2018200887	11/14/2019	Issued	Ophthalmologic Irrigation Solution and Method
United States of America	15/926,259	03/20/2018					Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	15/957,466	04/19/2018					Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	16/420,592	05/23/2019					Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	16/177,649	11/01/2018					Abandoned	Ophthalmologic Irrigation Solution and Method
Japan	2018-241032	07/30/2003	2019-43965	03/22/2019			Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	16/701,819	12/03/2019					Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	16/911,678	06/25/2020					Abandoned	Ophthalmologic Irrigation Solution and Method
Japan	2020-117688	07/30/2003	2020-169205	10/15/2020			Published	Ophthalmologic Irrigation Solution and Method
United States of America	17/130,565	12/22/2020					Abandoned	Ophthalmologic Irrigation Solution and Method
United States of America	17/366,659	07/02/2021					Pending	Ophthalmologic Irrigation Solution and Method
African Regional Industrial Property Organization	AP/P/2015/008459	10/23/2013					Allowed	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Botswana	AP/P/2015/008459	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Ghana	AP/P/2015/008459	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Gambia	AP/P/2015/008459	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection

Country Name	Application So.	Filing				Trip
Kenya	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Liberia	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Lesotho	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Malawi	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Mozambique	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Namibia	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Rwanda	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Sudan	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Sierra Leone	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
eSwatini	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Tanzania, United Republic of	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Uganda	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Zambia	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Zimbabwe	AP/P/2015/008459	10/23/2013			Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	17/405,269	08/18/2021			Pending	STABLE PRESERVATIVE-FREE MYDRIATIC AND ANTI- INFLAMMATORY

Country	Application So.	Filing	Production	Publication	Patent	Issue Date	Application	THE STATE OF THE S
N-2-18-4					Number			SOLUTIONS FOR INJECTION
United States of America	17/171,373	02/09/2021					Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Korea, Republic of	10-2021-7002992	10/23/2013	10-2021- 0018954	02/18/2021			Published	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
European Patent Convention	21167904.8	10/23/2013	3909572	11/17/2021			Published	STABLE PRESERVATIVE-FREE MYDRIATIC AND ANTI- INFLAMMATORY SOLUTIONS FOR INJECTION
Albania	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Austria	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Belgium	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Bulgaria	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Switzerland	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Cyprus, Republic of	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Czech Republic	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Germany	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Denmark	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Estonia	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Spain	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection

		Filme	Paramata	1000		Legal Date		Title
Finland	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
France	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United Kingdom	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Greece	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Croatia	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Hungary	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Ireland	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Iceland	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Italy	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Lithuania	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Luxembourg	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Latvia	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Monaco	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
North Macedonia	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Malta	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Netherlands	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free

Corner		Filing	Parlament		Parent			Title
				Date.				Mydriatic and Anti- Inflammatory Solutions for Injection
Norway	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Poland	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Portugal	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Romania	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Serbia	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Sweden	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Slovenia	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Slovakia	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
San Marino	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Bosnia and Herzegovina	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Turkey	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Montenegro	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Validated	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	16/944,609	07/31/2020					Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Malaysia	PI2020001054	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection
Japan	2019-036146	10/23/2013	2019-81798	05/30/2019			Abandoned	Stable Preservative-Free Mydriatic and Anti-

Country	Application (see	Filing	Publication	Parking	Patient	lesie Date	\$ 000110011001	
Same				0.9116	Number 			Inflammatory Solutions for Injection
Japan	2020-104619	10/23/2013	2020-147606	09/17/2020			Published	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Korea, Republic of	10-2019-7038220	10/23/2013			10-2211784	01/28/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Mexico	MX/a/2020/01259	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	16/738,546	01/09/2020					Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Argentina							Unfiled	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	16/213,758	12/07/2018					Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
India	201818046475	10/23/2013	201818046475 A	02/15/2019			Published	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	16/454,775	06/27/2019					Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Armenia	201590807	10/23/2013	201590807	11/30/2015	033811	11/27/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Azerbaijan	201590807	10/23/2013	201590807	11/30/2015	033811	11/27/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Belarus	201590807	10/23/2013	201590807	11/30/2015	033811	11/27/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Kyrgyz Republic	201590807	10/23/2013	201590807	11/30/2015	033811	11/27/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Kazakhstan	201590807	10/23/2013	201590807	11/30/2015	033811	11/27/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Russian Federation	201590807	10/23/2013	201590807	11/30/2015	033811	11/27/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Tajikistan	201590807	10/23/2013	201590807	11/30/2015	033811	11/27/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions

Course		Filing	Pathington	Parking	Patent	les de la lace	Application	
NHHE		17216	N 12	Date			Name	for Injection
Turkmenistan	201590807	10/23/2013	201590807	11/30/2015	033811	11/27/2019	Issued	Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection
China (People's Republic)	201810548093.X	10/23/2013	108721210	11/02/2018			Published	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Japan	2016-163544	10/23/2013	2016-196511	11/24/2016	6282699	02/02/2018	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	15/278,514	09/28/2016	US 2017- 0196838 A1	07/13/2017	9,855,246	01/02/2018	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Japan	2016-208082	10/23/2013	2017-14294	01/19/2017			Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Colombia	2017/14777	10/23/2013			38938	05/31/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Japan	2018-2514	10/23/2013	2018-58905	04/12/2018			Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Korea, Republic of	10-2017-7033129	10/23/2013	10-2017- 0128640	11/22/2017			Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	15/823,282	11/27/2017	2018-0085349 A1	03/29/2018			Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Hong Kong	16101601.1	10/23/2013	1213434A	07/08/2016	121343A	10/15/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Burkina Faso	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Benin	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Central African Republic	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Congo, Republic of	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Ivory Coast	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection

60010	Application	Filing	Publication	Publication	Patent	les de Dade	5 (1911) 11 (1911)	
Cameroon	1201500139	10/23/2013			17289	10/30/2015		Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Gabon	1201500139	10/23/2013			17289	10/30/2015		Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Guinea	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Equatorial Guinea	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Guinea-Bissau	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Comoros	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Mali	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Mauritania	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Niger	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Senegal	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Chad	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Togo	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Argentina	20130103855	10/23/2013	0093115	05/20/2015			Published	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Australia	2013201465	03/07/2013			2013201465	06/16/2016	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
New Zealand	628106	10/23/2013					Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
New Zealand	628398	10/23/2013			628398	07/01/2016	Issued	Stable Preservative-Free

Country		Filing	Publication	Publication	Patent	Issue Date	Application	
				2.11	Name of the second			Mydriatic and Anti- Inflammatory Solutions for Injection
Patent Cooperation Treaty	PCT/US13/66349	10/23/2013	WO2014/066485	05/01/2014			Lapsed	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	61/718,026	10/24/2012					Lapsed	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	61/736,179	12/12/2012					Lapsed	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	14/061,039	10/23/2013	US2014/023569 1A1	08/21/2014	9,066,856	06/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United States of America	14/721,151	05/26/2015	US2015/034292 8	12/03/2015	9,486,406	11/08/2016	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Brazil	BR112015009228 4	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Canada	2,887,772	10/23/2013	2887772	05/01/2014	2887772	02/21/2017	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Chile	201501078	10/23/2013			60361	08/17/2020	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
China (People's Republic)	201380055290.3	10/23/2013	104822265	08/05/2015			Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Israel	238439	10/23/2013	238439	06/30/2015			Published	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Japan	2015-539749	10/23/2013			6017053	10/07/2016	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Mexico	MX/a/2015/00508 9	10/23/2013			MX 382411 B	05/07/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
African Intellectual Property Organization (OAPI)	1201500139	10/23/2013			17289	10/30/2015	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
United Arab Emirates	510/2015	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Bahrain	BP 59/2015	10/23/2013					Pending	Stable Preservative-Free

		Filing Date						File
								Mydriatic and Anti- Inflammatory Solutions for Injection
Cuba	2015-0037	10/23/2013					Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Egypt	PCT 613/2015	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
European Patent Convention	13848382.1	10/23/2013	2911511	09/02/2015	2911511	04/14/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Iran (Islamic Republic of)	139450140003000 186	10/23/2013			91469	03/05/2017	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Laos	PT 362	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Indonesia	P-00201502326	10/23/2013			IDP000060556	07/15/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Sri Lanka	18205	10/23/2013					Allowed	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Malaysia	PI 2015001038	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
India	3029/DELNP/2015	10/23/2013	3029/DELNP/20 15 A	10/02/2015			Published	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Nigeria	F/P/2015/110	10/23/2013			RP: F/P/2015/110	09/18/2018	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Korea, Republic of	10-2015-7012282	10/23/2013	10-2015- 0068990	06/22/2015	10-1808394	12/06/2017	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Oman	OM/P/2015/00083	10/23/2013					Pending	Stable and preservative- and antioxidant-free mydriatic and anti- inflammatory ocular solutions containing ketorolac and phenylephrine for topical injection
Panama	90652	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Peru	544-2015	10/23/2013		07/09/2015			Abandoned	Stable Preservative-Free Mydriatic and Anti-

Country	A policina de la compansión de la compan	Filing	Publication	Publication	Patent	Issue Date	100	
N 1114		Dare		Date	Anniher		Status	Inflammatory Solutions for Injection
Philippines	1-2015-500850	10/23/2013	1-2015-500850	06/22/2015	1-2015-500850	07/21/2017	Issued	Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection
Qatar	QA/201504/00166	10/23/2013					Issued	Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection
Eurasian Patent Organization	201590807	10/23/2013	201590807	11/30/2015	033811	11/27/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Saudi Arabia	515360325	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
South Africa	2015/02684	10/23/2013	2015/02684	01/27/2016	2015/02684	01/27/2016	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Singapore	11201502602W	10/23/2013			11201502602 W	12/29/2016	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
African Regional Industrial Property Organization	AP/P/2015/008459	10/23/2013					Allowed	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Thailand	1501002140	10/23/2013	180780	10/18/2018			Published	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Colombia	15-109.621	10/23/2013					Abandoned	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Costa Rica	2015-0233	10/23/2013					Pending	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Algeria	150204	10/23/2013			10563	01/25/2021	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Ecuador	IEPI-2015-17331	10/23/2013	IEPI-2015-17331	06/30/2016			Published	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Georgia	AP2013013833	10/23/2013			0006891	09/10/2018	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Morocco	38096	10/23/2013	00038096	10/31/2016	38096	12/31/2019	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Moldova	A20150050	10/23/2013					Abandoned	Stable Preservative-Free Mydriatic and Anti-

	Application		Paralle	Parking				Fille
								Inflammatory Solutions for Injection
Ukraine	a 2015 05028	10/23/2013			0114650	07/10/2017	Issued	Stable Preservative-Free Mydriatic and Anti- Inflammatory Solutions for Injection
Uzbekistan	IAP20150175	10/23/2013			IAP 06469	04/28/2021	Issued	A STERILE LIQUID PHARMACEUTICAL FORMULATION AND A STERILE LIQUID DOSAGE FORM FOR PREPARING AN IRRIGATION SOLUTION
Vietnam	1-2015-01445	10/23/2013	1-2015-01445	07/27/2015	28439	04/22/2021	Issued	A sterile liquid pharmaceutical formulation comprising phenylephrine and ketorolac, preservative- fee and antioxidant-free
United States of America	62/086,133	12/01/2014					Lapsed	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
United Arab Emirates	P6000621/2017	11/30/2015					Pending	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Australia	2015355289	11/30/2015			2015355289	05/06/2021	Issued	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Brazil	1120170116480	11/30/2015					Pending	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Canada	2,967,687	11/30/2015	2967687	06/09/2016			Published	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Chile	2017001303	11/30/2015					Abandoned	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
China (People's Republic)	201580065093.9	11/30/2015	106999472	08/01/2017			Published	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Colombia							Unfiled	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
European Patent	15865551.4	11/30/2015	3226857	10/11/2017			Abandoned	Anti-Inflammatory and Mydriatic Intracameral

Country	Application So	Filing	Pathlication		Patent	lection (1916)		
Convention			\$11		Number			Solutions for Inhibition of Postoperative Ocular
Israel	252559	11/30/2015					Pending	Inflammatory Conditions Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Japan	2017-527859	11/30/2015	2018-500295	01/11/2018			Published	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Korea, Republic of	10-2017-7015573	11/30/2015	10-2017- 0088875	08/02/2017			Published	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Mexico	MX/a/2017/00682 9 I	11/30/2015					Pending	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
New Zealand	732418	11/30/2015					Pending	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Russian Federation	2017123221	1	RU 2017 123 221 A	01/09/2019	2750296	06/25/2021	Issued	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Saudi Arabia	517381639	11/30/2015					Pending	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
United States of America	15/836,772		US2018/028035 0 A1	10/04/2018			Abandoned	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
United States of America	14/953,806	11/30/2015	US 2016- 0279099 A1	09/29/2016			Abandoned	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Argentina	20150103758	11/30/2015	0102691	03/15/2017			Published	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Taiwan	104137247	11/11/2015	201620514	06/16/2016	705812	10/01/2020	Issued	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Patent Cooperation Treaty	PCT/US15/62929	11/30/2015	WO2016/089739	06/09/2016			Lapsed	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular

	Application No.	Piling Date	Polisication		Part of the second		1111
							Inflammatory Conditions
Hong Kong	18104336.5	11/30/2015	1244705	08/17/2018		Abandoned	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
United States of America	16/276,337		0175552A1	06/13/2019		Published	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Japan	2020-33111	11/30/2015	2020-79315	05/28/2020		Published	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Argentina		11/30/2015				In Process	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Taiwan	109129385	11/11/2015	202114657A	04/16/2021		Published	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
European Patent Convention	21 180685.6	11/30/2015				Pending	Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
United States of America	62/218,511	09/14/2015				Abandoned	Mydriatic and Anti- Inflammatory Composition Kits and Methods
United States of America	62/218,516	09/14/2015				Abandoned	Mydriatic and Anti- Inflammatory Composition Kits and Methods
United States of America	62/218,520	09/14/2015				Abandoned	Phenylephrine and Ketorolac Kits and Methods
United States of America	62/218,522	09/14/2015				Abandoned	Mydriatic and Anti- inflammatory Composition Kits and Methods
United States of America	62/394,844	09/15/2016				Abandoned	Mydriatic and Anti- Inflammatory Composition Kits and Methods
United States of America	62/394,857	09/15/2016				Abandoned	Mydriatic and Anti- Inflammatory Composition Kits and Methods
United States of America	62/394,873	09/15/2016				Abandoned	Mydriatic and Anti- Inflammatory Composition Kits and Methods
United States of America	62/394,882	09/15/2016				Abandoned	Mydriatic and Anti- Inflammatory Composition Kits and

Corner	Spalication So	Filing Base	Patricular	Particular Date	Parent Sumber	A positive states States	Title
							Methods
United States of America	62/559,831	09/18/2017					Mydriatic and Anti- Inflammatory Composition Kits and Methods
United States of America	62/559,841	09/18/2017					Mydriatic and Anti- Inflammatory Composition Kits and Methods
United States of America	62/559,844	09/18/2017					Mydriatic and Anti- Inflammatory Composition Kits and Methods
United States of America	62/559,848	09/18/2017					Mydriatic and Anti- Inflammatory Composition Kits and Methods

RECORDED: 02/22/2022